The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
about
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolismReview on genetic variants and maternal smoking in the etiology of oral clefts and other birth defectsA framework for assessing risks to children from exposure to environmental agents.Improving the risk assessment of lipophilic persistent environmental chemicals in breast milkPersistent pharmacokinetic challenges to pediatric drug developmentSulphate in pregnancyDeciphering the Developmental Dynamics of the Mouse Liver TranscriptomeDevelopmental expression of aldehyde dehydrogenase in rat: a comparison of liver and lung developmentHepatic Cytochrome P450 Activity, Abundance, and Expression Throughout Human DevelopmentDetoxiProt: an integrated database for detoxification proteinsClinical pharmacology in the adolescent oncology patient.Human milk biomonitoring data: interpretation and risk assessment issues.Effects of postnatal exposure to a mixture of polychlorinated biphenyls, p,p'-dichlorodiphenyltrichloroethane, and p-p'-dichlorodiphenyldichloroethene in prepubertal and adult female Sprague-Dawley rats.In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3Cleft lip and palate genetics and application in early embryological development.Flavin-containing monooxygenase S-oxygenation of a series of thioureas and thiones.Ethanol pharmacokinetics in neonates and infantsAn Update on Fetal Alcohol Syndrome-Pathogenesis, Risks, and Treatment.New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants.Dosing in neonates: special considerations in physiology and trial design.Hepatic differentiation of amniotic epithelial cells.Developmental and pediatric pharmacogenomics.Paediatric pharmacokinetics: key considerations.Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feedingRNA sequencing reveals dynamic changes of mRNA abundance of cytochromes P450 and their alternative transcripts during mouse liver development.Computational pharmacokinetics during developmental windows of susceptibility.Pharmacotherapy of pediatric HIV infectionMaternal obesity alters feto-placental cytochrome P4501A1 activity.Patterns of drug utilization in a neonatal intensive care unit.The pregnane X receptor in tuberculosis therapeutics.The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines.Physiological significance and expression of P450s in the developing eye.Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations.Developmental and tissue-specific expression of human flavin-containing monooxygenases 1 and 3.Cell-based models to study hepatic drug metabolism and enzyme induction in humans.Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans.The fate and effects of xenobiotics in human placenta.Clinical pharmacogenetics in pediatric patients.Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation
P2860
Q22251223-70178E53-716E-4CCD-A2F2-CBC661582A43Q24650568-CD331AE5-D7F7-48E8-B93F-2720D6A0DEEDQ24811017-01A58D22-3FB4-43F5-9646-F4AF49F86A9AQ26849356-209D697B-4CEE-434A-83DA-9911C416F059Q27023912-01CADAE5-B7BE-4A14-AD7D-58D081F7D01AQ28083379-B9FC8BBA-6AC0-4893-828C-0F301F785AFAQ28550476-C0FF5FE6-3D4E-4F25-AF47-9E5CB06233F3Q28564424-D184680A-E6AD-4B84-9ED2-D918D1D9842AQ28831360-015D52EE-47A2-435D-A998-7CC962166B09Q30427279-4CFA1E0A-4374-495D-B68E-6A849C38A6FDQ30497854-F1E8A2B1-E503-4D27-AB9C-706671A27382Q31006357-3F2C56BD-126C-4446-8F19-5908776EAF50Q33220095-87995B16-3702-434C-AF6D-00DED9670BB1Q33574651-2276B822-C9D5-4E86-8119-020FD4D02660Q33671456-47B82587-FFE5-47A2-86A9-750C4FBEC840Q33946752-05FF2374-110A-4358-BBF9-FAEC94619F4DQ34440525-1B6B1B00-7FCB-4A1C-A664-505120AE4634Q34532819-6D01F9A3-EB8C-446E-ABCA-226F536EC178Q34673712-239B363B-3220-4F4A-BD08-4048034363DCQ34716879-A9D4C520-8B2A-410E-927F-F13E51A9A28DQ35012484-3ABC3FF6-AA3D-471F-8069-D7CD61E04252Q35116112-25B72EA0-0617-4A94-A610-F0238D912378Q35135940-6A24A4B5-43DF-411A-9CCC-9CDDFD46081BQ35624622-0D16EB7D-4444-44B1-9FBD-6CCFE7CAA47DQ35827404-BFDA2288-84EE-48F7-8226-9BABB799DE7EQ35996442-0F7E4825-1B88-49D3-B5CC-CDFA7DE36BFDQ36195215-EAD69608-7B62-41D0-8166-EE39BBA14AFFQ36301325-DC75EE01-D3B3-4974-AC15-AB805EE4F825Q36417384-160E649A-F1B4-48FF-B3A7-9F4CB18F7FEEQ36428827-E3C5A06D-550F-4E8F-9C5F-9F80AA739CC8Q36451492-02075779-5F56-46C8-843B-0DCA9593775EQ36473486-E0E7FE7E-452D-4E94-8378-049B57D861EAQ36473511-C146A16C-9649-464A-81C7-81247651361EQ36544972-76A996E8-58FB-46E4-8BD0-927424D56926Q36545025-44F5A49E-F726-4EA6-8B19-B8684693F08CQ36572634-BC6B794D-0E85-4BC0-9EA8-1F2C7940BF79Q36625649-712959E1-432F-4B41-87F0-889D3E23FF09Q36835803-BE2232AC-DB00-445B-B6C7-017A6F47292EQ36989836-0BDF1BF4-EACD-492F-89A0-507CEF0193A7Q37062614-4DA2BAC2-E9C2-48F3-9D52-6C4788314E6B
P2860
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@ast
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@en
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@nl
type
label
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@ast
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@en
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@nl
prefLabel
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@ast
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@en
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@nl
P356
P1476
The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes.
@en
P2093
D Gail McCarver
Ronald N Hines
P304
P356
10.1124/JPET.300.2.355
P407
P577
2002-02-01T00:00:00Z